Analyse der Arzneimitteltherapie von Rheumapatienten im Erwachsenenalter : das Versorgungsgeschehen im Lichte der Leitlinienempfehlungen

The aim of this dissertation is to demonstrate the further developments in the provision of rheumatological health care with particular focus on evidence-based guideline recommendations. One of the issues to be examined is to identify gaps - defined as conditions of insufficient medical care between practical daily care and (theoretical) guideline recommendations differentiating various aspects of care. Are there still references about a lack of provison of medical care or is it possible to reveal further developments that can be assessed as positive respectively? Avenues for future action are to be pointed out against the background of these findings with regard to measures which have already been established as well as to aspired solutions in order to optimate the provision of rheumatological health care. A further glimpse of the future is disclosed by taking up the biosimilar-issue: As many bio-pharmaceuticals lose patent protection in coming years, biosimilar products are expected to play a key role in controlling pharmaceutical expenditure - while maintaining consistent quality of medical care. Assessing opportunities and challenges of these new medical products will round off this dissertation

Analyse der Arzneimitteltherapie von Rheumapatienten im Erwachsenenalter : das Versorgungsgeschehen im Lichte der Leitlinienempfehlungen

The aim of this dissertation is to demonstrate the further developments in the provision of rheumatological health care with particular focus on evidence-based guideline recommendations. One of the issues to be examined is to identify gaps - defined as conditions of insufficient medical care between practical daily care and (theoretical) guideline recommendations differentiating various aspects of care. Are there still references about a lack of provison of medical care or is it possible to reveal further developments that can be assessed as positive respectively? Avenues for future action are to be pointed out against the background of these findings with regard to measures which have already been established as well as to aspired solutions in order to optimate the provision of rheumatological health care. A further glimpse of the future is disclosed by taking up the biosimilar-issue: As many bio-pharmaceuticals lose patent protection in coming years, biosimilar products are expected to play a key role in controlling pharmaceutical expenditure - while maintaining consistent quality of medical care. Assessing opportunities and challenges of these new medical products will round off this dissertation